8AP Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginStrong revenue growth alongside an approximately 82% gross margin indicates improving product and royalty economics. If commercial adoption continues, this combination can provide meaningful operating leverage and support a more durable earnings base as the business scales.
Low Financial LeverageVery low leverage gives Agios financial flexibility while it funds commercialization and clinical development. A substantial asset base and limited debt burden reduce dependence on borrowing and improve the company’s ability to sustain strategic investment.
Commercial Launch TractionGrowing prescriptions and broad payer coverage provide evidence that AQVESME is gaining commercial access in its target market. Continued treatment conversion and reimbursement support could make product revenue increasingly important to the company’s longer-term growth.
Bears Say
Persistent Cash BurnHeavy operating and free cash outflows show that Agios is not yet funding its activities from internally generated cash. Continued burn could require sustained use of its capital base until commercial growth and operating leverage materially reduce losses.
Deep Operating LossesThe scale of current operating losses remains a significant fundamental weakness despite strong revenue growth. Achieving durable profitability will depend on converting commercial expansion into sufficient gross profit to absorb substantial research and corporate expenses.
Revenue And Rebate PressureReported revenue may be uneven because stocking effects and order timing can distort quarterly demand, while higher Medicaid exposure may reduce realized sickle cell revenue. These factors could make growth and margin progression less predictable during expansion.
Agios Pharma News
8AP FAQ
What was Agios Pharma’s price range in the past 12 months?
Currently, no data Available
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is CHF1.80B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is Nov 05, 2026 which is in 12 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Jul 30, 2026. The company reported -CHF1.394 earnings per share for the quarter, missing the consensus estimate of -CHF1.366 by -CHF0.029.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.03.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 59,701,880 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -CHF1.394 in its last earnings report, missing expectations of -CHF1.366. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Agios Pharma?
Currently, no hedge funds are holding shares in CH:8AP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agios Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF37.27 (― Upside)
CHF37.27 (― Upside)
Blogger Sentiment
Bullish
CH:8AP Sentiment 100%
Sector Average 66%
Sector Average 66%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.90%
12-Months-Change
Fundamentals
Return on Equity
-35.67%
Trailing 12-Months
Asset Growth
-24.66%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
8AP Company Deck
8AP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated substantial commercial momentum (AQVESME launch traction and U.S.-centric revenue), a meaningful near-term regulatory catalyst (Mitapivat PDUFA on Nov 1), and active pipeline expansion (cevidoplenib, AG-236, AG-181), supported by a strong cash position (~$1B). Offsetting these positives are elevated R&D and SG&A spending, a sizable net loss ($100.7M), quarter-to-quarter revenue variability (including a one-time $5M stocking benefit in Q2), and potential pricing/net revenue pressures for a sickle cell indication due to higher Medicaid mix and rebates. On balance, the operational and pipeline progress and the regulatory catalyst outweigh the financial and visibility challenges.View all CH:8AP earnings summaries8AP Stock 12 Month Forecast
Average Price Target
―Ultragenyx Pharmaceutical
―
Iovance Biotherapeutics
―
Intellia Therapeutics
―
Beam Therapeutics
―
Nurix Therapeutics
―